Drug intelligence / Profile preview

I-124-CPD-1028

Development stage: Phase 1
Lead developer: Centre for Probe Development and Commercialization
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

I-124-CPD-1028 is a radioconjugate composed of the insulin-like growth factor 1 receptor (IGF-1R) binding agent CPD-1028 and conjugated to the radionuclide iodine I 124. It is designed for potential tumor imaging upon positron emission tomography/computed tomography (PET/CT). Upon administration, I-124-CPD-1028 targets and binds to IGF-1R-expressing tumor cells, allowing for their visualization and assessment. IGF-1R is a receptor tyrosine kinase that is frequently overexpressed in various human cancers and plays a significant role in stimulating cellular proliferation, oncogenic transformation, and suppressing apoptosis. CPD-1028 is described as a novel Figitumumab-based iodine-residualizing radioimmunoconjugate suitable for imaging and radiotherapy.

Other names: iodine I 124 CPD-1028

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on I-124-CPD-1028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on I-124-CPD-1028.

Explore the full profile